Nice_老虎社区_美港股上老虎

q14n
2021-12-29

Nice

Why Did Intellia Soar in 2021 While Other Gene Editing Stocks Faltered? Crispr in Humans

Gene therapy-focused biotechs are engaged in the development of some of the most cutting-edge treatm

Why Did Intellia Soar in 2021 While Other Gene Editing Stocks Faltered? Crispr in Humans

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":696709725,"tweetId":"696709725","gmtCreate":1640759975835,"gmtModify":1640760300983,"author":{"id":3581245996241049,"idStr":"3581245996241049","authorId":3581245996241049,"authorIdStr":"3581245996241049","name":"q14n","avatar":"https://static.tigerbbs.com/9026569979a298d00d3912fffdcb270e","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":3,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Nice</p></body></html>","htmlText":"<html><head></head><body><p>Nice</p></body></html>","text":"Nice","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/696709725","repostId":1149303444,"repostType":4,"repost":{"id":"1149303444","pubTimestamp":1640759339,"share":"https://www.laohu8.com/m/news/1149303444?lang=&edition=full","pubTime":"2021-12-29 14:28","market":"us","language":"en","title":"Why Did Intellia Soar in 2021 While Other Gene Editing Stocks Faltered? Crispr in Humans","url":"https://stock-news.laohu8.com/highlight/detail?id=1149303444","media":"seekingalpha","summary":"Gene therapy-focused biotechs are engaged in the development of some of the most cutting-edge treatm","content":"<ul>\n <li>Gene therapy-focused biotechs are engaged in the development of some of the most cutting-edge treatments. Yet only one has had astandout year: Intellia Therapeutics.</li>\n <li>While its peers are all in the red for the year, as of yesterday, Intellia shares are&nbsp;up a whopping 120%year to date.</li>\n <li>What was the secret to Intellia's success? In June, the company demonstrated that its&nbsp;CRISPR candidate was able to genetically edit cells inside the liver. This is considered a major breakthrough and its shares immediately soared.</li>\n <li>None of Intellia's peers had this kind of development advancement, and as a result, they have languished. Intellia's breakthrough may place it ahead of competitors.</li>\n <li>In June, Seeking Alpha contributor Dan Schrack, who is very bullish on Intellia, said that \"NTLA-2001 has the&nbsp;potential to be considered a medical cure to a previously fatal disease.\" That disease is transthyretin amyloidosis (\"ATTR\").</li>\n <li>Intellia has both in-vivo and ex-vivo candidates in its pipeline, though there are more in the former.</li>\n</ul>\n<p><img src=\"https://static.tigerbbs.com/21a07c028d98baafc4898040cafd6e5c\" tg-width=\"1498\" tg-height=\"742\" referrerpolicy=\"no-referrer\"></p>\n<ul>\n <li>Several of its in-vivo candidates are partnered with Regeneron Pharmaceuticals (REGN+0.5%), an alliance that could help with research -- and funding -- in the future.</li>\n <li>Topping the list of worst performing gene editing stocks is Editas Medicine (EDIT+0.4%),down ~60%YTD.</li>\n <li>The company's lead candidate is EDIT-101, in preclinical stage for Leber Congenital Amaurosis 10 (LCA10), a genetic retinal disorder.</li>\n <li>With a neutral rating, contributor Jacob Braun today says the company \"does not have a drug pipeline to warrant its current valuation.\" He has a neutral rating.</li>\n <li>The second worst is CRISPR Therapeutics (CRSP-0.0%),down ~50%YTD.</li>\n <li>The company made news in April with&nbsp;an amended development agreement with Vertex Pharmaceuticals(VRTX+0.3%) for CTX001, an investigational CRISPR/Cas9-based gene editing therapy for sickle cell disease and transfusion-dependent beta-thalassemia.</li>\n <li>Edmund Ingham, a contributor,recommended buying a recent dip in CRISPR shares&nbsp;on the promise of the Vertex collaboration.</li>\n</ul>\n<p><img src=\"https://static.tigerbbs.com/a9074ffe942686a7202cb791ad8b0794\" tg-width=\"1843\" tg-height=\"622\" referrerpolicy=\"no-referrer\"></p>\n<ul>\n <li>Apelllis Pharmaceuticals (APLS-0.9%) is also down double digits YTD. Beam Therapeutics (BEAM-0.5%) and Caribou Biosciences (CRBU-1.8%) are down single digits, though Caribouhad its IPO in July.</li>\n</ul>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Did Intellia Soar in 2021 While Other Gene Editing Stocks Faltered? Crispr in Humans</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Did Intellia Soar in 2021 While Other Gene Editing Stocks Faltered? Crispr in Humans\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-29 14:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3783739-why-did-intellia-soar-in-2021-while-other-gene-editing-stocks-faltered-crispr-in-humans><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Gene therapy-focused biotechs are engaged in the development of some of the most cutting-edge treatments. Yet only one has had astandout year: Intellia Therapeutics.\nWhile its peers are all in the red...</p>\n\n<a href=\"https://seekingalpha.com/news/3783739-why-did-intellia-soar-in-2021-while-other-gene-editing-stocks-faltered-crispr-in-humans\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://seekingalpha.com/news/3783739-why-did-intellia-soar-in-2021-while-other-gene-editing-stocks-faltered-crispr-in-humans","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1149303444","content_text":"Gene therapy-focused biotechs are engaged in the development of some of the most cutting-edge treatments. Yet only one has had astandout year: Intellia Therapeutics.\nWhile its peers are all in the red for the year, as of yesterday, Intellia shares are up a whopping 120%year to date.\nWhat was the secret to Intellia's success? In June, the company demonstrated that its CRISPR candidate was able to genetically edit cells inside the liver. This is considered a major breakthrough and its shares immediately soared.\nNone of Intellia's peers had this kind of development advancement, and as a result, they have languished. Intellia's breakthrough may place it ahead of competitors.\nIn June, Seeking Alpha contributor Dan Schrack, who is very bullish on Intellia, said that \"NTLA-2001 has the potential to be considered a medical cure to a previously fatal disease.\" That disease is transthyretin amyloidosis (\"ATTR\").\nIntellia has both in-vivo and ex-vivo candidates in its pipeline, though there are more in the former.\n\n\n\nSeveral of its in-vivo candidates are partnered with Regeneron Pharmaceuticals (REGN+0.5%), an alliance that could help with research -- and funding -- in the future.\nTopping the list of worst performing gene editing stocks is Editas Medicine (EDIT+0.4%),down ~60%YTD.\nThe company's lead candidate is EDIT-101, in preclinical stage for Leber Congenital Amaurosis 10 (LCA10), a genetic retinal disorder.\nWith a neutral rating, contributor Jacob Braun today says the company \"does not have a drug pipeline to warrant its current valuation.\" He has a neutral rating.\nThe second worst is CRISPR Therapeutics (CRSP-0.0%),down ~50%YTD.\nThe company made news in April with an amended development agreement with Vertex Pharmaceuticals(VRTX+0.3%) for CTX001, an investigational CRISPR/Cas9-based gene editing therapy for sickle cell disease and transfusion-dependent beta-thalassemia.\nEdmund Ingham, a contributor,recommended buying a recent dip in CRISPR shares on the promise of the Vertex collaboration.\n\n\n\nApelllis Pharmaceuticals (APLS-0.9%) is also down double digits YTD. Beam Therapeutics (BEAM-0.5%) and Caribou Biosciences (CRBU-1.8%) are down single digits, though Caribouhad its IPO in July.","news_type":1},"isVote":1,"tweetType":1,"viewCount":726,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}